Pulmonary arterial hypertension (PAH) is a rare but well-known cardiovascular condition potentially associated with human immunodeficiency virus (HIV) infection and is currently recognized to be one of the most ominous noninfectious HIV complications. Although there is no clear evidence supporting the use of any medication for the treatment of HIV-related PAH, many of the currently available agents have been shown to exert some clinical benefits HIV-PAH patients. To date, no data are available regarding the potential effects of sitaxsentan, a selective endothelin type-A receptor antagonist, in this peculiar patient population. We report the case of a successful switch to sitaxsentan in a HIV-infected patient with PAH initially receiving bosentan who developed a late treatment-related side-effect.
Introduction
Pulmonary arterial hypertension (PAH) is a rare but well-known cardiovascular condition potentially associated with human immunodeficiency virus (HIV) infection and is currently recognized to be one of the most ominous non-infectious HIV complications [Simonneau et al. 2004; Archer and Rich, 2000; Mehta et al. 2000; Mesa et al. 1998 ]. Although there is no clear evidence supporting the use of any medication for the treatment of HIV-related PAH ], many of the currently available agents have been shown to exert some clinical benefits in case reports or series of HIV-PAH patients in New York Heart Association (NYHA) class III-IV [Pellicelli et al. 2001] . To date, no data are available regarding the potential effects of sitaxsentan, a selective endothelin type A (ET A ) receptor antagonist, in this peculiar patient population. We report the case of a successful switch to sitaxsentan in a HIV-infected patient with PAH initially receiving bosentan who developed a late treatment-related side-effect.
Case report
A 46-year-old man with positive blood exams for previous HIV infection was initially evaluated at our institute in April 2006 for exertional dyspnea and fatigue. He reported a marked limitation of physical activity in the previous 2-3 months. On admission his physical examination was substantially unremarkable. Laboratory analysis showed a slight elevation of alanine aminotransferase (ALT) 82 mU/ml, and aspartate aminotransferase (AST) 72 mU/ml. His six-min walk (6MW) distance was 338 m. The initial clinical suspicion of PAH associated to HIV infection was supported by transthoracic Doppler echocardiographic findings and subsequently confirmed by invasive hemodynamic assessment. The right heart catheterization revealed severe, precapillary PAH with a mean pulmonary artery pressure (mPAP) of 50 mmHg and a pulmonary capillary wedge pressure of 11 mmHg. PAH was not responsive to acute vasoreactivity testing with incremental doses of epoprostenol (8 ng/kg/min to 14 ng/kg/min) with virtually no change in mPAP (49 mmHg) at 14 ng/kg/min. The final diagnosis was, thus, NYHA functional class III HIV-related PAH and the patient started therapy consisting of bosentan, at an initial dose of 62.5 mg b.i.d., added to his background standard antiretroviral therapy with daily doses of tenofovir, lamivudine and atazanavir.
Initiation of therapy with bosentan was well tolerated and the agent was uptitrated to the full dose of 125 mg b.i.d. after 4 weeks, given also the stability of ALT and AST levels, 82 mU/ml and 69 mU/ml, respectively. After 12 weeks of treatment (8 weeks on full dose) the patient showed a significant improvement in exercise capacity, as indicated by a 32-m increase at the 6MW test. This was attended by an improvement in symptoms secondary to PAH with a NYHA functional class II and no deterioration in liver function. Thereafter the patient was followed by monthly liver function tests and regular clinical evaluation every 3-6 months. Clinical status and laboratory findings remained stable, although with a trend to an increase in liver transaminases (ALT 105 mU/ml and AST 93 mU/ml), over the following months.
In September 2007 the patient first reported the onset of nasal/sinus congestion. The patient was closely monitored in the following weeks and the nasal/sinus congestion was found to be persistent and subjectively poorly tolerated. Nasal/sinus congestion presented with no accompanying symptoms, such as headache or fever. The patient was initially treated with empiric antibiotic therapy and decongestants with no clinical benefit. Further laboratory testing (inclusive of antral lavage and cultures for bacterial and fungal pathogens) and radiologic evaluation ruled out both infective and allergic etiologies of the paranasal sinus disease. By exclusion, the patient's nasal/ sinus congestion was finally considered to be potentially related to bosentan therapy. In November 2007, after having obtained the patient's consent, we decided to withdraw treatment with bosentan and to introduce as a reasonable alternative the selective ET A antagonist sitaxsentan at a dose of 100 mg OD, given the satisfactory clinical and hemodynamic results achieved through endothelin receptorial antagonism. Sitaxsentan was well tolerated, ALT (112 mU/ml) and AST (99 mU/ml) levels did not substantially differ from preinitiation values, and the patient experienced a rapid and complete regression of nasal congestion in the first month after discontinuation of bosentan, with no deterioration in PAH-related symptoms. In April 2008, after 6 months of treatment with sitaxsentan, at the time of the most recent clinical assessment, the patient exhibited the same exercise tolerance as while on bosentan (368 m), was still in NYHA functional class II, free from nasal/ sinus congestion, and his ALT and AST levels were 125 mU/ml and 95 mU/ml, respectively.
Discussion
The estimated prevalence of HIV-PAH in HIVinfected is of 1:1200 (0.5%) as compared with the prevalence of 1-2:1;000;000 in the general population [Speich et al. 1991] . However, the actual prevalence of HIV-PAH is likely much higher, as most of the published studies evaluating HIV-PAH did not include asymptomatic cases. HIV-PAH is a progressive disease with no evidence-based treatment, and no study has so far established a single agent of choice for its treatment, albeit the dramatic progress accomplished over the past few years. Accordingly, the most frequently used agents in the treatment of HIV-PAH remain, in clinical practice, PAH-specific therapy and standard antiretroviral medications [Pellicelli et al. 2001 ]. This treatment is also that accepted in current guidelines .
Bosentan is an orally active, nonselective ET A / ET B receptor antagonist proven to prevent or even reverse the development of PAH, pulmonary vascular remodeling, and right ventricular hypertrophy [Rubin et al. 2002; Channick et al. 2001] . Currently, bosentan is the only ET receptor antagonist approved with a class I recommendation for the treatment of PAH in European guidelines ]. Bosentan was also recently shown to exert clinical benefits in a nonrandomized clinical trial of 16 patients with HIV-PAH and NYHA class III-IV, as indicated by improvements in 6 MW distance (þ91 AE 60 m, p50.001), NYHA class (14 out of 16 patients), hemodynamics (cardiac index: þ0.9 AE 0.7 l/min/ m 2 , p50.001), Doppler echocardiographic variables, and quality of life at 16-week follow-up [Sitbon et al. 2004 ].
As previously mentioned, sitaxsentan sodium is a highly selective ET A receptor antagonist, ET A :ET b
Therapeutic Advances in Respiratory Disease 3 (1) ratio46500:1, with an oral bioavailability490%, and a half-life of nearly 10 hours [Kedzierski et al. 2001] . Endothelin type A and B receptors mediate divergent effects in the pulmonary and peripheral vasculature [Humbert et al. 2004; Masaki et al. 1992] . From this point of view, more selective antagonism of the ET A receptors may be beneficial as it may spare the endothelin-clearance effects of ET B receptors.
So far the effects of sitaxsentan have been assessed in two controlled randomized trials, the Sitaxsentan To Relieve ImpaireD Exercise (STRIDE)-1 [Barst et al. 2004 ] and STRIDE-2 [Barst et al. 2006 ], for a total of 425 PAH patients (idiopathic, or associated with connective tissue disease or congenital heart disease) with NYHA class II-IV symptoms. Results from these trials have shown that sitaxsentan at a dose of 100 mg OD improves exercise capacity and functional class while increasing the time to clinical worsening in PAH patients [Barst et al. 2006 [Barst et al. , 2004 . Sitaxsentan 100 mg was also associated with a good safety and tolerability profile.
As a class, endothelin receptor antagonists, both selective and nonselective, have been reported to be associated with liver function abnormalities. However, this has lead to treatment discontinuation only very rarely. It has caused contraindication of this treatment in patients with baseline, that is, prior to treatment initiation, ALT and/or AST greater than three times the upper limit of normal (ULN) [Barst et al. 2006 [Barst et al. , 2004 Rubin et al. 2002; Channick et al. 2001 ]. An elevation greater than three times ULN in transaminases was found in 11% of patients receiving bosentan and in 3-5% patients receiving sitaxsentan in major trials [Barst et al. 2006 [Barst et al. , 2004 Rubin et al. 2002; Channick et al. 2001] .
Bosentan and sitaxsentan also share other rare side-effects including pedal edema, headache, nausea, fatigue, dizziness, flushing and nasal/ sinus congestion [Barst et al. 2006 [Barst et al. , 2004 Rubin et al. 2002; Channick et al. 2001] . The incidence of such side-effects did not substantially differ, over 18 weeks of follow-up, among the cohorts of patients enrolled in the STRIDE-2 randomized to sitaxsentan 100 mg s.i.d. or to open-label bosentan 125 b.i.d., although the study was not powered to assess direct comparisons between these two subgroups [Barst et al. 2006 ]. With regard to nasal/sinus congestion, this was reported in 7/61 and 5/60 patients in the sitaxsentan 100 mg s.i.d. and in the bosentan 125 mg b.i.d. groups, respectively, and did not usually constitute a cause of drug discontinuation [Barst et al. 2006 ]. In our patient, however, the symptom was unbearable and caused bosentan discontinuation.
To the best of our knowledge the present one is the first report of the use of sitaxsentan in a patient with HIV-related PAH. The observation of a late (nearly 18 months after treatment initiation) bosentan-related side-effect is quite unusual. However, the causal relation between therapy with bosentan and nasal congestion was confirmed by the prompt regression of this symptom after drug discontinuation. Given the good response in terms of exercise tolerance and functional class achieved through endothelin receptor blockade therapy, the switch to a selective agent such as sitaxsentan was regarded as the most reasonable therapeutic option, although not supported by available mechanistic and clinical data. Withdrawal of bosentan with concomitant introduction of sitaxsentan did not result in either short-term worsening of the clinical status or liver function. Moreover, the clinical benefits were maintained during the following 6 months of treatment with sitaxsentan up to the most recent available follow-up visit performed in April 2008, when a sustained beneficial effect of previous therapy with bosentan was unlikely. Although limited to only one patient, this observation may suggest a potential role for sitaxsentan in the treatment of patients with HIV-related PAH with an expected clinical benefit to endothelin antagonists' administration.
